

Table 6.6a
Immunosuppression Use for Induction, 1999 to 2008
Recipients with Pancreas Transplant Alone (PTA) Transplants

	Year of Transplant									
	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008
Transplants	139	134	168	181	160	183	199	173	208	223
With Immunosuppression Info	136	128	165	178	155	179	193	167	200	219
Induction Drugs										
ALG	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Atgam/NRATG/NRATS	8.1%	0.0%	0.0%	0.0%	1.3%	2.2%	0.0%	0.6%	1.0%	1.4%
OKT3	7.4%	4.7%	3.0%	3.4%	0.6%	0.0%	2.1%	5.4%	7.5%	6.4%
Thymoglobulin	30.1%	48.4%	49.1%	60.1%	45.2%	50.3%	48.2%	41.9%	41.5%	49.8%
Zenapax	30.1%	44.5%	34.5%	30.9%	8.4%	9.5%	5.2%	10.8%	7.0%	6.8%
Simulect	11.0%	9.4%	3.0%	3.9%	6.5%	0.0%	2.1%	2.4%	3.5%	4.6%
Campath	0.0%	0.0%	0.0%	1.1%	31.6%	41.3%	33.7%	24.0%	14.0%	11.4%
No Induction Drugs Recorded	37.5%	29.7%	38.8%	30.3%	18.1%	20.1%	16.6%	21.0%	33.5%	26.9%

Source: OPTN/SRTR Data as of May 4, 2009.

Notes:

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.